* Nuvation Bio Inc NUVB.N reported a quarterly adjusted
loss
of 9 cents per share for the quarter ended in June. The mean
expectation of six analysts for the quarter was for a loss of 11
cents per share.
* Reported revenue was zero; analysts expected zero.
* Nuvation Bio Inc's reported EPS for the quarter was a loss
of 9
cents.
* The mean earnings estimate of analysts had fallen by
about 1.5%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
* Nuvation Bio Inc shares had fallen by 2.2% this
quarter and
lost 8.3% so far this year.
* The company reported a quarterly loss of $20.64 million.
* Wall Street's median 12-month price target for Nuvation
Bio Inc
is $4.50
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
This summary was machine generated from LSEG Refinitiv data
August 4 at 06:17 a.m. UTC. All figures in US dollars unless
otherwise stated. QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2023 -0.11 -0.09 Beat
Mar. 31 2023 -0.10 -0.10 Met
Dec. 31 2022 -0.11 -0.10 Beat
Sep. 30 2022 -0.14 -0.12 Beat